Roberto's

Name

Roberto's

Legal name

北京爱游戏官网入口_爱游戏中国生化技术有限公司

Website

https://robertopizzeria.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

Leadman is a Beijing-based in vitro diagnostics company that develops, manufactures, and sells clinical chemistry reagents, chemiluminescence immunoassay analyzers, and biochemical analyzers to hospital laboratories and distributors across China and selected international markets.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• In vitro diagnostics
• Diagnostic reagents
• Clinical analyzers
• Chemiluminescence immunoassay
• Biochemical diagnostics

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. 体外诊断试剂销售: 爱游戏官网入口_爱游戏中国 generates revenue primarily from the sale of in vitro diagnostic reagents including biochemical reagents, immunodiagnostic (chemiluminescence) reagents, and molecular diagnostic products. Products are sold to hospitals, clinical laboratories, and distributors across China.
2. 诊断仪器销售与技术支持: Sale of self-developed diagnostic instruments including the CI1000全自动化学发光免疫分析仪 and BA800全自动生化分析仪, along with associated technical services and after-sales support.
3. 诊断仪器销售: Self-developed automated chemiluminescence immunoassay analyzer CI1000 has been successfully sold after its market launch at CMEF.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Roberto's (Leadman) manufactures and sells in vitro diagnostic reagents — including biochemical diagnostic reagents and immunodiagnostic (chemiluminescence) reagents — together with self-developed clinical analyzers such as the CI1000 fully automated chemiluminescence immunoassay analyzer and BA800 fully automated biochemical analyzer. Products are sold to hospitals, clinical laboratories, and regional distributors for clinical testing of tumor markers, hormones, infectious diseases, cardiac markers, and routine biochemistry panels.

Product overview

爱游戏官网入口_爱游戏中国 (Roberto's/Leadman) is a vertically integrated in vitro diagnostics (IVD) company offering a portfolio of diagnostic reagents and laboratory instruments. The product portfolio consists of the main 爱游戏官网入口_爱游戏中国 brand (covering biochemical diagnostic reagents), a 诊断试剂 (diagnostic reagents) product line spanning biochemical and immunoassay reagents for tumor markers, hormones, and infectious diseases, and a 实验仪器 (laboratory instruments) line featuring the self-developed CI1000全自动化学发光免疫分析仪 (automated chemiluminescence immunoassay analyzer) and BA800全自动生化分析仪 (automated biochemical analyzer). Subsidiary brands include 德赛诊断系统 (Shanghai) and 北京阿匹斯生物技术有限公司. The company also operates a fully automated reagent production line with four digital modules (配制, 灌装, 贴标, 包装). Products serve clinical laboratories across tumor markers, hormones, infectious diseases, cardiac markers, and metabolic testing.

Differentiator

Problem solved

Functional benefit

Brands

• CI1000: Self-developed Fully Automated Chemiluminescence Immunoassay Analyzer for tumor markers, hormones, infectious disease detection

Products and services

• Biochemical Diagnostic Reagents (诊断试剂) Biochemical reagent product line for clinical chemistry testing, sold to hospital clinical laboratories and diagnostic testing centers. Covers routine biochemistry panels and metabolic testing.
• Leadman Immunoassay Reagents (爱游戏官网入口_爱游戏中国 immunodiagnostic/chemiluminescence reagents) Chemiluminescence-based immunodiagnostic reagents for tumor marker, hormone, and infectious disease detection, sold to hospital clinical laboratories for use with the CI1000 analyzer.
• CI1000 Fully Automated Chemiluminescence Immunoassay Analyzer Self-developed fully automated chemiluminescence immunoassay analyzer with magnetic particle-based detection, supporting tumor marker, hormone, and infectious disease detection. Throughput up to 180+ tests/hour, wide linear range, ultra-low background interference. Sold to hospital clinical laboratories.
• BA800 Fully Automated Biochemical Analyzer (BA800全自动生化分析仪) Self-developed fully automated biochemical analyzer for clinical chemistry testing, sold to hospital clinical laboratories.
• IDS Fully Automated Biochemical Immunoassay Analyzer (IDS全自动生化免疫分析仪) Fully automated biochemical immunoassay analyzer co-developed with UK-based IDS (Immunodiagnostic Systems plc), obtained medical device registration certificate in 2014. Sold to hospital clinical laboratories.
• Desai Diagnostic Systems Reagents and Instruments (德赛诊断) Diagnostic reagents and instruments sold under the Desai subsidiary brand, providing additional immunodiagnostic and clinical chemistry products for hospital clinical laboratories.
• Beijing Apis Biotechnology Molecular Diagnostics Products (北京阿匹斯生物技术) Wholly-owned subsidiary specializing in molecular diagnostics products, including COVID-19 detection products (CE certified in 2020) and other molecular diagnostics solutions. Sold to hospital and clinical laboratories.

Quantifiable outcome

• 全自动化学发光免疫分析仪CI1000 — 最高180+ tests/hour, 百万级宽线性范围, 超微量灵敏度, 背景干扰接近零值
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• 苏州立禾生物coreStrategic or Co-development Partner · 20 December 2024爱游戏官网入口_爱游戏中国 and Suzhou Lihe Bio formally signed a strategic cooperation agreement to jointly develop and expand the IVD market, leveraging complementary product portfolios and market channels.
• 俄罗斯VT公司 (Russia VT Company)coreStrategic or Co-development Partner · 30 October 2024爱游戏官网入口_爱游戏中国 and Russian VT Company reached a strategic cooperation to jointly develop overseas market layout and construction, expanding international presence in the Russian market.
• 高博医疗集团coreStrategic or Co-development Partner · 18 May 2023爱游戏官网入口_爱游戏中国 and Gaobo Medical Group established a strategic partnership to jointly build a high-level scientific and technological innovation platform, combining clinical research capabilities with diagnostic product development.
• 润达医疗coreStrategic or Co-development Partner · 28 December 2021爱游戏官网入口_爱游戏中国 and Runda Medical reached a strategic cooperation to leverage Runda's IVD distribution network and supply chain capabilities in the Chinese hospital market.
• 奥森多 (Ortho Clinical Diagnostics / DiaSorin)coreTechnology or Integration · 20 March 2019爱游戏官网入口_爱游戏中国 and Ortho Clinical Diagnostics launched the MPA project (collaborative development/marketing of immunodiagnostic products), representing a strategic technology and go-to-market partnership.
• Enigma诊断 (Enigma Diagnostics)coreStrategic or Co-development Partner · 23 October 2014爱游戏官网入口_爱游戏中国 partnered with Enigma Diagnostics to enter the molecular diagnostics sector, expanding from biochemical and immunoassay diagnostics into the rapidly growing molecular diagnostics market.
• 德赛诊断系统 (Desai Diagnostic Systems)coreTechnology or Integration · 17 October 2014爱游戏官网入口_爱游戏中国 partnered with international diagnostics giant 德赛诊断 (Desai), acquiring a controlling stake to expand product line and enhance market share in the Chinese IVD market. 德赛诊断系统（上海）有限公司 became a subsidiary of 爱游戏官网入口_爱游戏中国.
• IDS (Immunodiagnostic Systems holding plc)coreStrategic or Co-development Partner · 1 May 2013爱游戏官网入口_爱游戏中国 signed a co-development contract with UK-based IDS (Immunodiagnostic Systems holding plc) to jointly develop diagnostic reagents for the Chinese market. IDS全自动生化免疫分析仪 obtained medical device registration certificate.
• 北京经济技术开发区诊断试剂创新联盟minorStrategic or Co-development Partner · 2 December 2010爱游戏官网入口_爱游戏中国 participated in the creation of the Beijing Economic Development Zone Diagnostic Reagent Innovation Alliance, serving as a council member unit and taking responsibility for organizing and coordinating alliance activities.
• 德赛诊断系统（上海）有限公司coreTechnology or IntegrationSubsidiary of 爱游戏官网入口_爱游戏中国 acquired through acquisition of a controlling stake in 德赛诊断系统（上海）有限公司. Focuses on immunodiagnostic systems and maintains a research collaboration with Shanghai Tongren Hospital.
• 克林顿健康拓展行动 (CHAI / Clinton Health Access Initiative)minorStrategic or Co-development Partner爱游戏官网入口_爱游戏中国, as council member of the Beijing Economic Development Zone IVD Innovation Alliance, helped organize the Clinton Health Access Initiative seminar connecting Chinese IVD manufacturers with CHAI's procurement network for Africa and developing countries.

Scale indicators6 records

Recent moves12 records

Expansion highlights5 records

Emerging players

• Da An Gene (达安基因): Chinese molecular diagnostics specialist and IVD reagent provider with strong PCR and clinical testing capabilities. Comparable to Leadman's expansion into molecular diagnostics via the Enigma partnership and Beijing Apis subsidiary.
• Runda Medical (润达医疗): Chinese IVD distributor and channel partner; Leadman's 2021 strategic partner. Overlaps in IVD distribution and channel services, with growing proprietary reagent manufacturing — a partial overlap with Leadman's product strategy.

Broad incumbents

• Mindray Medical (迈瑞医疗): China's largest medical device and IVD company, offering a comprehensive IVD platform including chemiluminescence immunoassay, biochemistry, hematology, and molecular diagnostics. Directly competes with Leadman's CI1000 and biochemical analyzer offerings in similar hospital segments.
• Roche Diagnostics: Global IVD market leader with the cobas immunoassay and clinical chemistry platforms. Dominant competitor in tier-3 Chinese hospitals and the standard against which Leadman's CI1000 and BA800 must benchmark.
• KingMed Diagnostics (金域医学): China's leading third-party medical laboratory network with strong reference laboratory and specialty testing capabilities. Comparable to Leadman's CNAS-accredited reference laboratory service business and potential customer in the same hospital channel.
• Ortho Clinical Diagnostics (QuidelOrtho): Multinational IVD company and Leadman's strategic technology partner (MPA project, 2017/2019). Comparable in immunoassay focus and shares distribution channels with Leadman in selected Chinese hospital accounts.

Direct peers

• Yhlo Biotech (亚辉龙): Chinese IVD company with strong focus on chemiluminescence immunoassay and autoimmune/infectious disease diagnostics. Direct competitor in tier-2 and tier-3 hospital segments where Leadman has historically concentrated.
• Autobio Diagnostics (安图生物): Chinese IVD company specializing in immunoassay (chemiluminescence), microbiology, and clinical chemistry reagents with proprietary automated analyzers. Head-to-head competitor with Leadman in immunology and biochemistry segments across Chinese hospital laboratories.
• Snibe Diagnostic (新产业生物): Leading Chinese chemiluminescence immunoassay (CLIA) specialist with globally installed MAGLUMI series analyzers. Direct competitor to Leadman's CI1000 in tumor markers, hormones, and infectious disease panels.
• Maccura Biotechnology (迈克生物): China-based IVD manufacturer with a similar full-stack product portfolio spanning clinical chemistry, immunoassay, hematology, and rapid diagnostics. Comparable scale and channel structure to Leadman, with overlapping target hospital segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/roberto's

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roberto's